Coeo Labs is a medtech startup based in Bengaluru, India, that develops critical-care devices such as VAPCare and Saans for ICU and neonatal patients.

This Startup Deep Dive explains what Coeo Labs does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Coeo Labs in Brief

• What it is: Coeo Labs is an Indian Critical care medtech company based in Bengaluru.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Coeo Labs makes VAPCare, an intelligent secretion and oral hygiene management system aimed at preventing ventilator-associated pneumonia in intubated ICU patients.
• It also makes Saans, a portable neonatal CPAP intended for newborns with respiratory distress syndrome in resource-constrained settings, including during transport.
• The company says Saans works without electricity and pressurised gas (company-stated).
• Funding: Not disclosed in public sources reviewed.

Coeo Labs Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Coeo Labs?

Coeo Labs operates in the Critical care medtech space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Coeo Labs.

• Coeo Labs makes VAPCare, an intelligent secretion and oral hygiene management system aimed at preventing ventilator-associated pneumonia in intubated ICU patients.
• It also makes Saans, a portable neonatal CPAP intended for newborns with respiratory distress syndrome in resource-constrained settings, including during transport.
• The company says Saans works without electricity and pressurised gas (company-stated).
• VAPCare was highlighted during COVID-19 as helping doctors and patients (reported).

The Origin Story of Coeo Labs

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Nachiket Deval, Nitesh Kumar Jangir.
• Coeo Labs was formed in October 2014 in Bengaluru by Nachiket Deval and Nitesh Kumar Jangir, who met through a clinical-needs programme at a hospital.
• It operates as a division or subsidiary of InnAccel Technologies, a Bengaluru medtech company; InnAccel is also its largest shareholder.
• Nitesh Jangir was named on a Forbes 30 Under 30 list, as described in a 2022 profile.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Critical care medtech sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• October 2014: company formed in Bengaluru.
• November 2016: non-equity assistance from MassChallenge (reported).
• August 2017: seed round from Elevate 100 (reported).
• March 2019: Saans described as recently launched, billed as the world's first portable neonatal CPAP (company-stated).
• 2019: part of the World Economic Forum Tech Pioneers cohort.

Coeo Labs Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Non-equity assistance from MassChallenge, November 2016, amount undisclosed (reported).
• Seed round from Elevate 100, August 2017, amount undisclosed (reported).
• Millennium Alliance awardee, a grant-based recognition (reported).
• No later round was found.

How Does Coeo Labs Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells medical devices and consumables to hospitals and neonatal units; parent InnAccel planned commercial operations in India, Southeast Asia and Africa and partnerships to enter the US, EU, China and Japan.
• Targets low-cost, power-independent devices for low-resource settings.

The Numbers: Coeo Labs Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY19 revenue Rs 1.0 lakh, down 94% from Rs 17.0 lakh in FY18; FY19 net loss about Rs 2.2 crore on expenses of Rs 1.8 crore (aggregator).
• Two employees in the latest filing (2019).
• Saans addresses over 160,000 annual deaths of premature babies in India from respiratory distress, about a third during transport (company-stated).

Market Opportunity for Coeo Labs

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Neonatal and ICU respiratory care in India and other low-resource markets.
• InnAccel set a target of 20 products by 2025 and 25 million lives impacted (company-stated).

Technology and Product at Coeo Labs

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Saans was conceptualised with CAMTech partners Dr Kristian Olson (USA) and Dr Data Santorino (Uganda).
• Saans is designed as a power-independent, low-skill, low-cost neonatal CPAP; VAPCare is an intelligent secretion and oral hygiene management system.

Team and Culture at Coeo Labs

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• As of March 2019, founders collectively held 62.5% equity and InnAccel held 37.5% (reported).
• Nachiket Deval has since moved on and is now an investment manager at Grand Challenges Canada.

Coeo Labs Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Coeo Labs

• Publicly available funding and filing data is dated, with the latest reported round in 2017 and the latest filing in 2019.
• Reported revenue fell sharply from FY18 to FY19 and the company is tiny in headcount.
• No named direct competitors or later commercial data were found.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Coeo Labs Growth Outlook: What to Watch

• InnAccel aimed for commercial operations in India, Southeast Asia and Africa within three years of 2019 and 20 products by 2025.
• Current commercial status is unclear from recent sources.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Coeo Labs can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Coeo Labs Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Coeo Labs

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Coeo Labs.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Coeo Labs

Studying a company in the Critical care medtech space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Coeo Labs.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Coeo Labs as a Startup

• Customer clarity: Can Coeo Labs name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Coeo Labs is part of India’s growing Critical care medtech ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Coeo Labs FAQs: Frequently Asked Questions

What is Coeo Labs?

Coeo Labs is a medtech startup based in Bengaluru, India, that develops critical-care devices such as VAPCare and Saans for ICU and neonatal patients. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Coeo Labs?

Coeo Labs was founded by Nachiket Deval, Nitesh Kumar Jangir, and the company reports a founding year of 2014.

How much funding has Coeo Labs raised?

No reliable total funding figure is disclosed in the public sources reviewed. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Coeo Labs make money?

Coeo Labs earns revenue from its Critical care medtech products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Coeo Labs?

Reported rivals include Conventional bubble CPAP systems. See the competitor comparison above for how they differ.

What are the main risks for Coeo Labs?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Freedom From Diabetes — Freedom From Diabetes says it has taken 5,000+ type 2 diabetics off medication since a 2011 Pune start | Minimalist — Minimalist, the D2C skincare brand HUL agreed to buy at Rs 2,955 crore, built Rs 515 crore revenue in four years. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.